Multisystem Inflammatory Syndrome Therapies in Children (MISTIC) Comparative Effectiveness Study

Who is this study for? Children with Multisystem Inflammatory Syndrome
Status: Completed
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY

In March 2020, children exposed to the virus that causes the COVID-19 illness, SARS-CoV-2, presented with fever and significant inflammation about a month after exposure to the virus. Some children were sick enough to require care in the intensive care unit for what came to be known as Multisystem Inflammatory Syndrome-Children (MIS-C).The clinical presentation shared many features with Kawasaki disease (KD), a self-limited inflammation that can cause ballooning of the arteries of the heart. Thus, physicians reached for many of the therapies used to treat children with KD. Despite the surge of COVID-19 cases and children continuing to present with MIS-C, there are no data that guide the choice of therapy. Thus, the investigators have designed a study to determine which combination of therapies is most effective in helping children with MIS-C recover quickly.

Eligibility
Participation Requirements
Sex: All
Maximum Age: 20
Healthy Volunteers: f
View:

• An individual aged \<21 years presenting with

‣ Fever (\>38.0°C for ≥24 hours; may be by subjective report) AND

⁃ Two or more of the following (from two different systems; e.g. one from cardiac and one from mucocutaneous):

‣ Cardiac

∙ Hypotension

∙ Shock

∙ Arrhythmia

∙ Tachycardia

∙ Left ventricular ejection fraction \<55%

∙ Valvulitis

∙ Coronary artery enlargement (LAD or RCA Z-score ≥ 2.5)

∙ Pericardial effusion Gastrointestinal

∙ Diarrhea

∙ Nausea/vomiting

∙ Significant abdominal pain Immunologic

∙ Lymphadenopathy (unilateral cervical or diffuse) Mucocutaneous

∙ Bilateral conjunctival injection

∙ Extremity swelling or erythema

∙ Rash

∙ Lip erythema/Strawberry tongue Neurologic

∙ Altered mental status

∙ Focal neurological deficits

∙ Headache

∙ Meningismus

⁃ Laboratory evidence of inflammation, including but not limited to, an elevated C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, procalcitonin, D-dimer, ferritin, lactic acid dehydrogenase (LDH), neutrophilia, lymphopenia or hypoalbuminemia AND

⁃ No alternative plausible diagnoses based on clinical judgement AND

⁃ Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or suspected COVID-19 exposure AND

⁃ Parent or legal guardian (or self if at least 18 years old) able and willing to provide informed consent and subject willing and able to provide assent when appropriate.

Locations
United States
California
Rady Children's Hospital
San Diego
Michigan
Children's Hospital Michigan
Detroit
Time Frame
Start Date: 2020-12-22
Completion Date: 2024-04-25
Participants
Target number of participants: 73
Treatments
Active_comparator: Infliximab
Infliximab will be administered as a single IV dose of 10 mg/kg over 2 hours.
Active_comparator: Methylprednisilone (steroids)
Methylprednisilone (steroids) will be administered as 2 mg/kg IV or orally divided every 12 hours. At the time of hospital discharge the patient will be given a steroid taper that will take at least 3 weeks to complete.
Active_comparator: Anakinra
Anakinra will be administered at a dose of 8 mg/kg/day IV or SQ with 100 mg every 6 hours as the max dose. This is discontinued with a taper during the hospitalization over 2-4 days once a patient is stable with significantly improved clinical course and laboratory profile.
Sponsors
Collaborators: Children's Hospital of Michigan
Leads: University of California, San Diego

This content was sourced from clinicaltrials.gov